Stage III Cutaneous Melanoma AJCC v7 Completed Phase 1 / 2 Trials for Aldesleukin (DB00041)
| Indication | Status | Phase |
|---|---|---|
| DBCOND0091046 (Stage III Cutaneous Melanoma AJCC v7) | Completed | 1 / 2 |
| clinicaltrials.gov Identifier | Title | Purpose | Drugs |
|---|---|---|---|
| NCT01740557 | Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma | Treatment |